Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
Diabetes Res Clin Pract. 2013 Aug;101(2):106-22. doi: 10.1016/j.diabres.2013.03.010. Epub 2013 May 1.
AIMS: Even though the Middle East and North Africa (MENA) region had the highest comparative prevalence of diabetes in 2012, little is known about the nuances of diabetes risk and capacity to address the burdens. To provide a comprehensive overview, we reviewed the literature on diabetes in the MENA region. METHODS: We conducted a systematic search in PubMed between January 1990 and January 2012 for studies on diabetes in the MENA region without language restriction. RESULTS: There was a paucity of country-specific epidemiology data in the region. Diabetes prevalence varied widely across studies, from 2.5% in 1982 to 31.6% in 2011. Older age and higher body mass index were the most strongly associated risk factors for diabetes. Among people with diabetes, over half did not meet recommended care targets. In addition, macrovascular and microvascular complications were observed in 9-12% and 15-54% of diabetes population, respectively. CONCLUSIONS: This review suggests a need for more representative surveillance data in this noteworthy focal point of the global diabetes epidemic. Such actions will not only help to understand the actual burden of diabetes but also motivate actions on design and implementation of diabetes prevention and control programs.
目的:尽管中东和北非(MENA)地区在 2012 年的糖尿病患病率最高,但对该地区糖尿病风险的细微差别及其应对负担的能力却知之甚少。为了提供全面的概述,我们对 MENA 地区的糖尿病文献进行了综述。
方法:我们在 PubMed 中进行了系统检索,检索时间为 1990 年 1 月至 2012 年 1 月,检索语言不限,以获取有关 MENA 地区糖尿病的研究。
结果:该地区缺乏特定国家的流行病学数据。糖尿病的患病率在研究中差异很大,从 1982 年的 2.5%到 2011 年的 31.6%。年龄较大和较高的体重指数是与糖尿病最密切相关的风险因素。在糖尿病患者中,超过一半的人未达到推荐的护理目标。此外,分别有 9-12%和 15-54%的糖尿病患者出现大血管和微血管并发症。
结论:这篇综述表明,需要在这个全球糖尿病流行的重要焦点地区进行更具代表性的监测数据。这些行动不仅有助于了解糖尿病的实际负担,而且还能激励制定和实施糖尿病预防和控制计划。
Diabetes Res Clin Pract. 2013-5-1
Diabetes Res Clin Pract. 2013-12-1
Int J Infect Dis. 2016-3
Niger Med J. 2024-11-6
BMC Public Health. 2023-12-16
Evid Based Complement Alternat Med. 2022-5-5